Herpes Virus as a Potential Cure for Childhood Brain Cancer
21 mins read

Herpes Virus as a Potential Cure for Childhood Brain Cancer

Every year, thousands of children worldwide are diagnosed with brain cancer, one of the most challenging and devastating forms of pediatric illness. Despite advancements in medical science, brain tumours remain the leading cause of cancer-related deaths in children under 14. However, an unexpected ally in the fight against this deadly disease has emerged: the herpes virus. This surprising discovery has opened up new avenues of research and hope, suggesting that a virus commonly associated with cold sores might be vital to curing childhood brain cancer.

Childhood brain cancer encompasses various types of brain tumours that affect children, with medulloblastoma and gliomas being among the most common. These cancers pose unique challenges due to their location in the brain and the developing nature of children’s bodies. Current treatments, including surgery, chemotherapy, and radiation, often come with significant side effects and varying degrees of success. The need for more effective and less harmful treatment options is paramount.

Read more: Halle Berry’s Truth: Perimenopause, Not Herpes

Understanding Childhood Brain Cancer

Types and Statistics

Childhood brain cancer is a term that encompasses various types of brain tumours that affect children. The most common types include:

  1. Medulloblastoma is the most frequent type of malignant brain tumour in children. It originates in the cerebellum or posterior fossa, the lower back part of the brain. Medulloblastomas account for about 20% of all pediatric brain tumours.
  2. Gliomas: Gliomas are tumours that arise from glial cells, which support and protect the neurons in the brain. There are several subtypes of gliomas, including:
    • Astrocytomas can be low-grade (pilocytic astrocytomas) or high-grade (glioblastomas). Low-grade astrocytomas are the most common brain tumours in children.
    • Ependymomas: These develop from ependymal cells lining the ventricles of the brain and the centre of the spinal cord.
    • Brainstem Gliomas: These occur in the brainstem and affect vital functions like breathing and heart rate. Diffuse intrinsic pontine gliomas (DIPGs) are particularly aggressive and challenging to treat.
  3. Ependymomas: These tumours develop from the cells lining the brain’s ventricles and the spinal cord’s central canal. They account for about 5% of childhood brain tumours.
  4. Craniopharyngiomas: These benign tumours occur near the pituitary gland and can affect hormone production and vision. They are not cancerous but can cause significant health problems due to their location.


  • Brain tumours are the most common solid tumours in children, representing about 25% of pediatric cancers.
  • Each year, approximately 4,300 children in the United States are diagnosed with a brain or central nervous system tumour.
  • The overall 5-year survival rate for children with brain cancer is around 75%, but this varies widely depending on the tumour type and location.
  • Survivors often face long-term health issues due to the aggressive treatments required and the sensitive nature of brain tissue.

The impact of childhood brain cancer extends beyond survival rates. The disease and its treatment can lead to significant cognitive, physical, and emotional challenges for the child and their family. These can include learning disabilities, growth and developmental delays, and psychological effects.

Current Treatments and Limitations

The standard treatments for childhood brain cancer include:

  1. Surgery: The primary goal is to remove as much of the tumour as possible while minimizing damage to surrounding brain tissue. Surgery is often the first step in treating brain tumours, but its success depends on the tumour’s size, type, and location.
  2. Chemotherapy involves using drugs to kill cancer cells or stop them from growing. It can be administered orally, intravenously, or directly into the cerebrospinal fluid. Physicians often combine it with surgery and radiation therapy.
  3. Radiation Therapy: High-energy radiation destroys cancer cells or inhibits their growth. It benefits tumours that cannot be entirely removed by surgery or recur.

Limitations and Side Effects:

  • Surgery: While effectively removing the bulk of the tumour, surgery carries risks such as infection, bleeding, and damage to healthy brain tissue. Complete removal is often challenging, especially for tumours in critical brain areas.
  • Chemotherapy: Chemotherapy can affect both cancerous and healthy cells, leading to side effects like nausea, vomiting, hair loss, and an increased risk of infections. Long-term use can also cause secondary cancers and impact the developing brain.
  • Radiation Therapy: Radiation can damage healthy brain tissue, leading to cognitive deficits, hormonal imbalances, and growth problems. Young children are particularly vulnerable to these side effects, which can significantly affect their quality of life.

The Herpes Virus

What is the Herpes Virus?

The herpes virus is a large family of viruses known for causing various diseases in humans and animals. The most well-known types of herpes viruses include:

  1. Herpes Simplex Virus Type 1 (HSV-1):
    • Primary Infection: HSV-1 primarily causes oral herpes, leading to cold sores or fever blisters around the mouth and face.
    • Transmission: HSV-1 is highly contagious and spreads readily through direct contact with herpes sores, saliva, or skin surfaces around the infected area.
    • Prevalence: HSV-1 infects approximately 67% of the global population under age 50.
  2. Herpes Simplex Virus Type 2 (HSV-2):
    • Primary Infection: HSV-2 primarily causes genital herpes, resulting in sores and blisters in the genital and anal regions.
    • Transmission: It is primarily transmitted through sexual contact.
    • Prevalence: About 13% of the global population aged 15-49 is infected with HSV-2.
  3. Varicella-Zoster Virus (VZV):
    • Primary Infection: VZV causes chickenpox, a highly contagious disease with an itchy, blister-like rash.
    • Reactivation: Later in life, the virus can reactivate to cause shingles, a painful rash often affecting one side of the body.
    • Prevalence: Most people contract chickenpox during childhood, making VZV widespread.
  4. Epstein-Barr Virus (EBV):
    • Primary Infection: EBV primarily causes infectious mononucleosis, or “mono,” characterized by fever, sore throat, and swollen lymph nodes.
    • Association with Cancer: EBV also links to certain types of cancers, including Burkitt’s lymphoma and nasopharyngeal carcinoma.
    • Prevalence: More than 90% of adults worldwide have contracted EBV.
  5. Cytomegalovirus (CMV):
    • Primary Infection: CMV often causes asymptomatic infections or mild flu-like symptoms but can be severe in immunocompromised individuals and newborns.
    • Transmission: It is spread through bodily fluids such as saliva, urine, blood, and breast milk.
    • Prevalence: Between 50% and 80% of adults in the United States are infected with CMV by age 40.

Herpes Virus and Its Re-engineering

Oncolytic Virotherapy:

Oncolytic virotherapy is an innovative cancer treatment strategy that uses genetically modified viruses to infect and kill cancer cells while selectively sparing normal cells. The herpes simplex virus (HSV) has become a prominent candidate for oncolytic virotherapy due to its ability to be engineered for safety and specificity.

Read more: Genital Herpes And Its Influence On Brain Shrinkage

How the Herpes Virus Can Be Genetically Modified:

  1. Attenuation of Virulence: The herpes virus can be altered to reduce its ability to cause disease in healthy cells. This is achieved by deleting or mutating specific viral genes responsible for replication in normal tissues, ensuring that the virus replicates preferentially in cancer cells with defective antiviral responses.
  2. Incorporation of Tumor-Specific Promoters: By inserting tumour-specific promoters into the viral genome, the replication of the herpes virus can be controlled by active elements primarily in cancer cells. This ensures that the virus multiplies mainly within tumour cells.
  3. Insertion of Therapeutic Genes: The herpes virus can be engineered to carry genes encoding immune-stimulatory proteins, cytokines, or prodrug-converting enzymes. These therapeutic genes can enhance the immune response against the tumour or convert non-toxic prodrugs into toxic compounds within the tumour environment, increasing the effectiveness of the treatment.
  4. Enhancing Immune System Activation: Modified herpes viruses can be designed to express antigens that stimulate the patient’s immune system to recognize and attack cancer cells. This dual approach kills cancer cells through viral infection and promotes a systemic anti-tumor immune response.
  5. Preventing Virus Spread to Normal Cells: To enhance safety, the virus can be engineered to express proteins that prevent it from spreading to healthy cells. For example, deletion of the ICP34.5 gene in HSV-1 restricts its ability to replicate in normal neurons, reducing the risk of neurovirulence.

Examples of Oncolytic HSV in Cancer Treatment:

  • T-VEC (Talimogene Laherparepvec): An FDA-approved oncolytic HSV-1 for treating advanced melanoma. T-VEC is modified to produce GM-CSF (granulocyte-macrophage colony-stimulating factor), which boosts the immune response against cancer cells.
  • Clinical Trials for Brain Cancer: Experimental oncolytic HSV treatments, such as G207 and M032, are being tested in clinical trials for gliomas and other brain cancers. These trials aim to determine the safety and efficacy of oncolytic HSV in targeting and destroying brain tumour cells.

The re-engineering of the herpes virus represents a promising frontier in cancer therapy. It offers a targeted, multifaceted approach to treating childhood brain cancer that has the potential to overcome the limitations of traditional treatments.

The Science Behind Herpes as a Cancer Treatment

Selective Infection and Destruction of Cancer Cells

The herpes simplex virus (HSV) can be genetically modified to become an effective oncolytic virus, targeting and destroying cancer cells while sparing healthy tissue. The mechanism involves several critical steps:

  1. Genetic Modification for Selectivity:
    • Attenuation of Virulence: Key viral genes that enable HSV to replicate in normal cells are deleted or mutated. For instance, the ICP34.5 gene, crucial for viral replication in normal cells, is often deleted. This allows the virus to replicate selectively in cancer cells, which have impaired antiviral defences.
    • Insertion of Tumor-Specific Promoters: Active Promoters are inserted only into the viral genome of cancer cells, ensuring the virus replicates primarily within tumour cells.
  2. Lytic Cycle Activation:
    • Once inside the cancer cell, the modified HSV enters its lytic cycle, hijacking its machinery to replicate. This replication process leads to the production of new viral particles.
    • The infected cancer cell eventually bursts (lyses), releasing the new viral particles and infecting neighbouring cancer cells, continuing the cycle of infection and destruction.
  3. Delivery of Therapeutic Genes:
    • The virus can be engineered to carry genes that produce therapeutic proteins, such as cytokines (e.g., GM-CSF) that stimulate an immune response or enzymes that convert prodrugs into active chemotherapeutic agents within the tumour microenvironment.

Immune System Response

The immune system plays a dual role in oncolytic virotherapy:

  1. Direct Viral Destruction:
    • The viral infection of cancer cells can directly destroy tumours through the lytic cycle, causing cancer cell death and tumour reduction.
  2. Immune Activation:
    • The lysis of cancer cells releases tumour-associated antigens into the bloodstream. These antigens are picked up by dendritic cells and presented to T cells, activating a systemic anti-tumor immune response.
    • Oncolytic viruses like HSV can be engineered to express immune-stimulatory molecules (e.g., GM-CSF), further enhancing the immune response and recruiting immune cells to the tumour site.
    • This leads to a robust immune attack on both the primary and metastatic cancer cells, contributing to long-term tumour control and potential remission.

Preclinical Studies and Research

Key Preclinical Studies

  1. Modified HSV-1 in Glioma Models:
    • Study: Researchers used a modified HSV-1 virus (G207) in animal models of glioma.
    • Findings: The virus selectively replicated in glioma cells, significantly reducing tumour size and improving survival rates in mice.
    • Breakthrough: This study demonstrated the potential of oncolytic HSV-1 to target and destroy brain tumours with minimal impact on normal brain tissue.
  2. Combination Therapy with Immune Checkpoint Inhibitors:
    • Study: A combination of oncolytic HSV and immune checkpoint inhibitors (anti-PD-1) was tested in animal models of glioblastoma.
    • Findings: The combination therapy enhanced anti-tumour immune responses, leading to more effective tumour eradication and prolonged survival than either treatment alone.
    • Breakthrough: This highlighted the potential for combining oncolytic virotherapy with immunotherapy to improve outcomes in brain cancer treatment.
  3. Engineering HSV to Express Therapeutic Genes:
    • Study: Researchers engineered modified HSV to express cytokines like IL-12 and GM-CSF in preclinical models of pediatric brain cancer.
    • Findings: The engineered virus enhanced anti-tumour activity, stimulating immune solid responses and reducing tumour burden.
    • Breakthrough: This study demonstrated that HSV can serve as a vector to deliver therapeutic genes, enhancing its oncolytic effects and promoting systemic immunity.

Read more: Navigating Herpes Symptoms on the Cervix

Significant Findings and Breakthroughs

  • Safety and Efficacy: Preclinical studies have consistently shown that oncolytic HSV can safely be administered with limited toxicity to normal tissues, making it a viable option for clinical development.
  • Tumour Selectivity: The genetic modifications ensure that HSV selectively targets and destroys cancer cells, minimizing collateral damage to healthy cells.
  • Immune System Engagement: Oncolytic HSV’s ability to stimulate a systemic anti-tumour immune response is a significant advantage, potentially leading to long-lasting tumour control and prevention of metastasis.
  • Clinical Translation: These preclinical successes have paved the way for clinical trials to test the safety and efficacy of oncolytic HSV in human patients with various types of brain cancer.

Clinical Trials and Real-world Applications

Clinical trials are essential for evaluating the safety and effectiveness of new treatments before they can be widely adopted. Several clinical trials are currently investigating the use of genetically modified herpes simplex virus (HSV) as a treatment for childhood brain cancer, primarily focusing on gliomas and other aggressive brain tumours.

Current Clinical Trials Involving HSV for Childhood Brain Cancer

  1. G207 Clinical Trial:

    • Objective: To assess the safety and efficacy of G207, a genetically modified HSV-1, in treating pediatric high-grade gliomas.
    • Phase: Phase I
    • Details: Researchers have engineered G207 to selectively replicate in tumour cells, causing their destruction while sparing healthy brain tissue. The trial aims to determine the maximum tolerated dose and to monitor any adverse effects.
    • Progress: Preliminary results indicate that G207 is well-tolerated and may offer therapeutic benefits, with some patients experiencing tumour reduction
  2. M032 Clinical Trial:

    • Objective: To evaluate the safety and therapeutic potential of M032, another modified HSV-1 designed to express IL-12, an immune-stimulating cytokine, in patients with recurrent or progressive pediatric brain tumours.
    • Phase: Phase I/II
    • Details: The trial aims to determine the safety, optimal dosing, and initial efficacy of M032 in enhancing anti-tumour immune responses and controlling tumour growth.
    • Progress: Early findings indicate that M032 is safe and shows promise in inducing immune responses against tumours, leading to tumour stabilization in some patients.
  3. HSV G47Δ Clinical Trial:

    • Objective: To test the efficacy of G47Δ, a third-generation oncolytic HSV, in treating pediatric brain tumours, including glioblastoma.
    • Phase: Phase II
    • Details: G47Δ has been modified to enhance its ability to stimulate the immune system and improve tumour selectivity. The trial focuses on measuring tumour response rates and overall survival.
    • Progress: Preliminary data suggest that G47Δ effectively reduces tumour size and prolongs survival in a subset of patients.

Phases of Clinical Trials

  1. Phase I:
    • Purpose: To evaluate the modified HSV’s safety, tolerability, and optimal dosing in a small group of patients.
    • Goals: Determine the maximum tolerated dose, identify any adverse effects, and establish preliminary evidence of efficacy.
    • Participants: Usually involves a small number of patients with advanced or refractory brain tumours who have not responded to standard treatments.
  2. Phase II:
    • Purpose: To further assess the efficacy and safety of the treatment in a larger group of patients.
    • Goals: Confirm the treatment’s effectiveness, monitor side effects, and refine dosing regimens.
    • Participants: Involve a larger group of patients, often with specific brain tumours, to gather more comprehensive data on the treatment’s impact.
  3. Phase III:
    • Purpose: To compare the new treatment against the current standard of care in a large, randomized trial.
    • Goals: Provide definitive evidence of efficacy and safety, support regulatory approval, and identify any long-term side effects.
    • Participants: Involves hundreds to thousands of patients across multiple centres, providing robust data for regulatory review.

Aim of These Trials

The primary aim of these clinical trials is to establish the safety and efficacy of oncolytic HSV as a viable treatment for childhood brain cancer. By demonstrating that these modified viruses can selectively target and destroy tumour cells while sparing healthy tissue, researchers hope to offer a new, less toxic treatment option for pediatric brain tumours. Additionally, these trials aim to harness the immune-stimulating properties of the modified HSV to achieve long-term tumour control and improve overall survival rates for young patients.

Real-world Applications

The success of these clinical trials could lead to the development of new oncolytic virotherapy treatments that provide significant benefits over existing therapies. These benefits include:

  • Targeted Treatment: Enhanced selectivity for cancer cells, reducing damage to healthy tissues.
  • Immune Activation: Stimulation of the immune system to recognize and attack cancer cells, potentially leading to long-term remission.
  • Reduced Side Effects: There are fewer and less severe side effects than traditional chemotherapy and radiation.
  • Combination Therapy: Potential to be combined with other treatments, such as immune checkpoint inhibitors, to enhance overall efficacy.

As these clinical trials progress, they bring hope for a new era in the treatment of childhood brain cancer, offering more effective and less harmful options for young patients and their families.


Q1: Is the herpes virus treatment safe for children?

Balanced Answer: Modified herpes simplex virus (HSV) therapies, such as G207 and M032, have generally demonstrated good tolerability in pediatric patients with manageable side effects during early-phase clinical trials, indicating promise for treating brain cancer in children with herpes virus treatment. However, further research is necessary to assess its safety profile fully. However, as with any experimental treatment, there are inherent risks and limited long-term safety data. Continued monitoring and larger-scale trials will provide more comprehensive safety assessments and help determine the therapy’s overall safety for children.

Q2: How does the herpes virus specifically target cancer cells?

Explanation: Genetic modifications enhance the ability of modified herpes simplex virus (HSV) therapies to infect and replicate within cancer cells selectively, sparing normal cells. Key strategies include:

  • Deletion or mutation of viral genes that are essential for replication in normal cells but dispensable for replication in cancer cells.
  • Incorporation of tumour-specific promoters that drive viral replication primarily in cancer cells.
  • Expression of therapeutic genes that enhance immune responses or induce cancer cell death, specifically within the tumour microenvironment. These modifications allow the virus to exploit the unique characteristics of cancer cells, such as altered signalling pathways and weakened antiviral defences, while minimizing harm to healthy tissues.

Q3: Are there any side effects associated with this treatment?

Discussion: Modified herpes virus therapies for cancer show promise but may lead to specific side effects. Common side effects reported in clinical trials include flu-like symptoms (e.g., fever, fatigue), local injection site reactions, and transient neurological symptoms. Serious adverse events, such as immune-related toxicities or neurologic complications, are rare but can occur, especially with higher doses or systemic administration of the virus. Overall, the side effects are generally manageable, and efforts are ongoing to optimize dosing regimens and minimize risks through careful patient selection and monitoring.

Q4: When might this treatment become widely available?

Insights: The timeline for widespread availability of herpes virus-based treatments for childhood brain cancer hinges on ongoing clinical trials, regulatory approvals, and healthcare integration. If clinical trials continue to show promise and regulatory approval is obtained from agencies like the FDA, broader availability could be expected within 5-10 years. Further research, including larger-scale trials and long-term follow-up studies, will be essential to establish efficacy and safety and ensure equitable access for all patients.

Q5: How can I learn more or support this research?

Resources and Ways to Contribute: To learn more about herpes virus-based treatments for childhood brain cancer and support ongoing research efforts, consider the following:

  • Stay informed: Follow updates from reputable sources, such as medical journals, research institutions, and advocacy organizations specializing in pediatric oncology.
  • Participate in clinical trials: If eligible, consider enrolling to contribute to scientific advancement and potentially benefit from cutting-edge treatments.
  • Donate to research institutions, non-profit organizations, or crowdfunding campaigns dedicated to advancing pediatric cancer research and developing new therapies.
  • Advocate for funding by raising awareness about the importance of funding for pediatric cancer research and supporting policies prioritizing funding for childhood cancer initiatives.

Read more: Why Herpes Could Be The Key To Curing Childhood Brain Cancer.